LEADER 03668nam  22006255  450 
001 9910863166203321
005 20240619143416.0
010   $a3-030-56619-6
024 7 $a10.1007/978-3-030-56619-7
035   $a(CKB)4100000011469492
035   $a(MiAaPQ)EBC6356684
035   $a(DE-He213)978-3-030-56619-7
035   $a(PPN)269661204
035   $a(EXLCZ)994100000011469492
100   $a20200923d2020      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases /$fedited by Christopher L. Cioffi
205   $a1st ed. 2020.
210   $cSpringer International Publishing$d2020
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020.
215   $a1 online resource (IX, 272 p. 1 illus.) 
225 1 $aTopics in Medicinal Chemistry,$x1862-247X ;$v35
311   $a3-030-56618-8 
327   $aAn Overview of Retinal Diseases and Current Ocular Drug Discovery -- Ocular Pharmacokinetics and Drug Delivery Challenges -- Models of Pathologies Associated with Age-related Macular Degeneration and Their Utilities in Drug Discovery -- Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease -- Targets and Strategies toward the Development of Therapeutics for Diabetic Retinopathy and Diabetic Macular Edema -- Recent Developments for the Treatment of Glaucoma -- Emerging Gene Therapy Treatments for Retinal Degenerative Diseases. .
330   $aThis book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerging gene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy.
410  0$aTopics in Medicinal Chemistry,$x1862-247X ;$v35
606   $aMedicinal chemistry
606   $aOphthalmology
606   $aPharmaceutical chemistry
606   $aMedical genetics
606   $aMedicinal Chemistry
606   $aOphthalmology
606   $aPharmaceutics
606   $aClinical Genetics
615  0$aMedicinal chemistry.
615  0$aOphthalmology.
615  0$aPharmaceutical chemistry.
615  0$aMedical genetics.
615 14$aMedicinal Chemistry.
615 24$aOphthalmology.
615 24$aPharmaceutics.
615 24$aClinical Genetics.
676   $a615.19
702   $aCioffi$b Christopher L.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910863166203321
996   $aDrug delivery challenges and novel therapeutic approaches for retinal diseases$92520068
997   $aUNINA